$4.39
8.16% yesterday
Nasdaq, Jun 13, 10:15 pm CET
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Aptevo Therapeutics Inc Stock price

$4.39
-2.41 35.44% 1M
-77.41 94.63% 6M
-81.81 94.91% YTD
-573.55 99.24% 1Y
-191,774.01 100.00% 5Y
-3,646,715.61 100.00% 10Y
-3,646,715.61 100.00% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.39 8.16%
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Key metrics

Market capitalization $3.07m
Enterprise Value $930.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.10m
Free Cash Flow (TTM) Free Cash Flow $-23.71m
Cash position $2.14m
EPS (TTM) EPS $-325.02
Short interest 1.39%
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

Buy
100%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.84 9.84
14% 14%
-
- Research and Development Expense 14 14
15% 15%
-
-24 -24
14% 14%
-
- Depreciation and Amortization 0.31 0.31
38% 38%
-
EBIT (Operating Income) EBIT -24 -24
14% 14%
-
Net Profit -24 -24
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
one day ago
SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 16-19, 2025, in Boston, MA. The confe...
Neutral
Accesswire
23 days ago
SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share ("Common Stock"), at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on May 23, 2025, at 5:01 p.m.
Neutral
Accesswire
about one month ago
9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML Cohort 2 enrollment is complete, and Cohort 3 is now enrolling SEATTLE, WA / ACCESS Newsw...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 37
Founded 2016
Website aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today